National Differences For Pharmacovigilance Requirements In Europe.
Webinar date & time: March 7th 15:00 CET
Join our webinar on “Navigating National Differences in Setting up a Pharmacovigilance System in Europe.” This session will discuss the regulations and guidelines to consider when implementing a pharmacovigilance system in Europe.
From country-specific reporting requirements to cultural considerations, we will cover the key factors you must consider to ensure compliance and effective pharmacovigilance practices across the region. Whether you’re a pharmaceutical company looking to expand into the European market, or an existing player looking to optimize your pharmacovigilance processes, this webinar will provide valuable insights and practical tips for success.
The webinar will lead by our field experts, who share their experiences and best practices. So let’s dive in and explore the complexities and opportunities of pharmacovigilance in Europe.
Register here!
Albert Befki, MSc
Head of Global Pharmacovigilance Operations
Albert is a pharmacovigilance expert with over 11 years of experience in the field. He has vast experience in different pharmacovigilance operations, from literature monitoring, vendor management, global and local case processing oversight, to safety database management. Before joining Biomapas, Albert held several strategic pharmacovigilance roles in various outsourcing service providers. He has extensive leadership experience in the pharma industry, which led him to become the Head of Pharmacovigilance Operations at Biomapas.
Setting up Pharmacovigilance In Europe?
Let’s talk how we can team up to conduct them effectively and ensure smooth processes.
Other content that might interest you:
Local Literature Surveillance Challenges and Specifics in the EU, CIS and LATAM regions
PV legislation introduced by the European Commission in 2012 and GVP guidelines together with local requirements committed each MAH to perform literature review in countries where their products are present. Compliance with mandatory requirements and guidelines is not always a simple task when local requirements and specifics come along. In this article, we will take a closer look at these challenges and specifics for local literature surveillance in different regions as EU, CIS and LATAM.
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)
On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.
Harmonization of EAEU GVP: CIS is getting more vigilant than ever before
On the 6-7 March, Biomapas Pharmacovigilance Department management and team from the CIS region participated in a meeting in Minsk. It was dedicated to strengthening collaboration between the team members as well as updating knowledge on latest PV trends. We discussed the most recent releases of legislation, such as Eurasian Economic Union Good Pharmacovigilance Practice harmonization and the importance of a teamwork approach with Biomapas’ PV Project Manager CIS, Aliaksandr Bakshtanovich, MD.
